Your session is about to expire
← Back to Search
Study Summary
This trial will study the effects of GLP-1 drugs on the blood levels of 3 common medications. The hypothesis is that their effects will be minimal.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- You have a serious medical condition now or in the past.Your body mass index (BMI) falls between 30 and 45.4.You possess no clinically significant abnormalities.Your body mass index (BMI) falls between 30.0 and 45.4.
- Group 1: Cohort 2: Semaglutide
- Group 2: Cohort 1: PF-07081532
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this research still recruiting test subjects?
"As advertised on clinicaltrials.gov, this research project is not presently accepting participants. Originally posted January 19th 2023 and last updated a few days later, the study has yet to resume its recruitment efforts. Though inactive at present, there are 923 other trials that are actively seeking patients for their studies."
To what degree are patients exposed to risk when taking Cohort 1: PF-07081532?
"Cohort 1: PF-07081532 has limited data gathered from Phase 1, so the safety score was evaluated as a 1 by the Power team."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger